Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sandoz and Biocon strike global biosimilars alliance

Executive Summary

Sandoz has formed an exclusive global alliance with Biocon to co-develop and market “next-generation biosimilars” in the immunology and oncology arenas. Neither the number nor the identity of the targeted molecules have been disclosed, but Biocon said the partnership covered “multi-billion dollar opportunities” through molecules in “early stages of development”. The partners will “share responsibility for end-to-end development, manufacturing, and global regulatory approvals”, and will split costs and profits from marketing the biosimilars equally.

You may also be interested in...

Sandoz Reveals Biosimilar Denosumab Program

As Sandoz reported its second-quarter financial results, the firm revealed details of a previously unannounced development program for biosimilar denosumab.

Biocon’s Biosimilar Ambitions Get A Boost With European Site Approval

Leading Indian biotech firm Biocon has got the green light for a biosimilar manufacturing facility from Europe’s drug regulator, paving the way for the company’s growing biosimilars portfolio to gain greater European market access.

Novartis Sees Space For Sandoz But In A Slimmer Streamlined Form

Sandoz has a place within Novartis as a more autonomous unit, the Swiss group’s CEO Vas Narasimhan says. But the generics and biosimilars division will have to sharpen up, aided by a 7% workforce cut.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts